Pharmaceutical Research and Development

Pharmaceutical Research and Development (R&D) refers to the comprehensive process of discovering, developing, and bringing new medicines to market. The process begins with understanding the disease and investigating drug interactions with living organisms, ultimately aiming to develop safe and effective treatments that can improve or even save lives.

During drug discovery research, researchers employ state-of-the-art technology to screen for and identify highly effective compounds and conduct basic research using external resources. This stage involves target identification by understanding the disease mechanism and identifying biological targets for intervention, followed by compound screening where thousands to millions of compounds are tested to identify potential drug candidates. Researchers then perform lead optimization by refining promising compounds to improve efficacy, safety, and pharmacokinetic properties, and conduct pre-clinical research using laboratory and animal studies to evaluate biological activity and toxicity before human testing.

The identified drug candidates then proceed to the drug development stage, where researchers lay the groundwork for filing and approval around the world. This stage includes physicochemical and biological property evaluation to assess the compound’s characteristics and behavior, quality assurance to ensure the compound meets quality standards and regulatory requirements, and process chemistry research to develop methods for large-scale synthesis and manufacturing. Formulation development creates the final drug product format such as tablets, injections, or capsules, while stability testing evaluates how the drug degrades over time under various conditions.

Drug candidates that clear development research are elevated to the clinical research stage, which is the longest and most expensive phase of drug development. Phase I clinical trials test the drug in small groups of healthy volunteers ranging from 20 to 100 people to evaluate safety, dosage range, and side effects. Phase II clinical trials test the drug in larger groups of patients from 100 to 300 people with the target disease to assess efficacy and further evaluate safety. Phase III clinical trials test the drug in large patient populations from 1,000 to 3,000 people to confirm efficacy, monitor side effects, and compare with existing treatments. After successful clinical trials, drug candidates that are approved by regulatory authorities such as the FDA or EMA can be launched on the market.